BioCentury | Sep 7, 2018
Strategy

Thinking beyond Bi

Following the resignation of Jingquan Bi, early signs for continued biopharma regulatory reform in China remain positive. But the IP reforms spearheaded by Bi look to have fallen off the government’s priority list, and there...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Nov 18, 2017
Regulation

Measuring regulatory outcomes

EMA wants to increase the use of real-world evidence and digital health to better understand the impact of pharmacovigilance decisions on patient outcomes. Pharmacovigilance decisions fall along a broad continuum, from small changes such as...
BioCentury | Nov 14, 2017
Regulation

Rules of engagement

An upcoming publication from the National Health Council on good practices for sponsor-patient interactions could help companies overcome fears that their outreach could be construed as promotional. Several executives told BioCentury that having guardrails established...
BioCentury | Aug 18, 2017
Company News

IBM, JDRF pinpointing T1D risk factors with machine learning

IBM Corp. (NYSE:IBM) and JDRF (New York, N.Y.) partnered to identify risk factors for Type I diabetes in children by applying IBM’s machine learning algorithms to data from JDRF research programs. JDRF spokesperson Kristy Evans...
BioCentury | Jun 27, 2017
Financial News

Provention raises $28.4M in series A

Autoimmune and inflammatory disease prevention and interception play Provention Bio Inc. (Lebanon, N.J.) said it raised $28.4 million in a series A round from the Johnson & Johnson Innovation-JJDC Inc. arm of Johnson & Johnson...
BioCentury | Jun 8, 2017
Company News

J&J taps Mammen for R&D job; Hait to lead external innovation

Johnson & Johnson (NYSE:JNJ) hired Mathai Mammen to succeed William Hait as global head of R&D. Hait will take on a newly created role as global head of external innovation. Mammen is joining J&J from...
BioCentury | Feb 24, 2017
Clinical News

A T-cell gene signature in infants could predict Type I diabetes

German researchers published a gene signature found in T cells from six month old infants that preceded the development of β cell autoantibodies in those at high risk for Type I diabetes. The paper was...
BioCentury | Feb 3, 2017
Company News

Weizmann Institute of Science, DayTwo, J&J deal

The Janssen Human Microbiome Institute (JHMI) of Johnson & Johnson partnered with DayTwo and the Weizmann Institute to develop a microbiome-based nutritional recommendation platform. JHMI and J&J's Disease Interception Accelerator (DIA) arm will evaluate whether...
BioCentury | Feb 2, 2017
Company News

Caelus investment among J&J's microbiome deals

The Janssen Human Microbiome Institute (JHMI) of Johnson & Johnson (NYSE:JNJ) announced three microbiome-related deals Thursday, including an equity investment in cardiometabolic company Caelus Health (Amsterdam, the Netherlands). J&J’s Johnson & Johnson Innovation-JJDC Inc. venture...
Items per page:
1 - 10 of 103
BioCentury | Sep 7, 2018
Strategy

Thinking beyond Bi

Following the resignation of Jingquan Bi, early signs for continued biopharma regulatory reform in China remain positive. But the IP reforms spearheaded by Bi look to have fallen off the government’s priority list, and there...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Nov 18, 2017
Regulation

Measuring regulatory outcomes

EMA wants to increase the use of real-world evidence and digital health to better understand the impact of pharmacovigilance decisions on patient outcomes. Pharmacovigilance decisions fall along a broad continuum, from small changes such as...
BioCentury | Nov 14, 2017
Regulation

Rules of engagement

An upcoming publication from the National Health Council on good practices for sponsor-patient interactions could help companies overcome fears that their outreach could be construed as promotional. Several executives told BioCentury that having guardrails established...
BioCentury | Aug 18, 2017
Company News

IBM, JDRF pinpointing T1D risk factors with machine learning

IBM Corp. (NYSE:IBM) and JDRF (New York, N.Y.) partnered to identify risk factors for Type I diabetes in children by applying IBM’s machine learning algorithms to data from JDRF research programs. JDRF spokesperson Kristy Evans...
BioCentury | Jun 27, 2017
Financial News

Provention raises $28.4M in series A

Autoimmune and inflammatory disease prevention and interception play Provention Bio Inc. (Lebanon, N.J.) said it raised $28.4 million in a series A round from the Johnson & Johnson Innovation-JJDC Inc. arm of Johnson & Johnson...
BioCentury | Jun 8, 2017
Company News

J&J taps Mammen for R&D job; Hait to lead external innovation

Johnson & Johnson (NYSE:JNJ) hired Mathai Mammen to succeed William Hait as global head of R&D. Hait will take on a newly created role as global head of external innovation. Mammen is joining J&J from...
BioCentury | Feb 24, 2017
Clinical News

A T-cell gene signature in infants could predict Type I diabetes

German researchers published a gene signature found in T cells from six month old infants that preceded the development of β cell autoantibodies in those at high risk for Type I diabetes. The paper was...
BioCentury | Feb 3, 2017
Company News

Weizmann Institute of Science, DayTwo, J&J deal

The Janssen Human Microbiome Institute (JHMI) of Johnson & Johnson partnered with DayTwo and the Weizmann Institute to develop a microbiome-based nutritional recommendation platform. JHMI and J&J's Disease Interception Accelerator (DIA) arm will evaluate whether...
BioCentury | Feb 2, 2017
Company News

Caelus investment among J&J's microbiome deals

The Janssen Human Microbiome Institute (JHMI) of Johnson & Johnson (NYSE:JNJ) announced three microbiome-related deals Thursday, including an equity investment in cardiometabolic company Caelus Health (Amsterdam, the Netherlands). J&J’s Johnson & Johnson Innovation-JJDC Inc. venture...
Items per page:
1 - 10 of 103